An acetylated polysaccharide-PTFE membrane-covered stent for the delivery of gemcitabine for treatment of gastrointestinal cancer and related stenosis

Biomaterials

Volumn 32, Issue 14, 2011, Pages 3603-3610

  Moon, Sumi ^a   Yang, Su Geun ^b,c   Na, Kun ^a  

^a The Catholic University of Korea   (South Korea)

^b Utah Inha DDS and Advanced Theapeutics Research Center   (South Korea)

^c Inha University School of Medicine   (South Korea)

Author keywords

Covered stents; Gastrointestinal cancer; Gemcitabine; Nonvascular drug eluting stents (DES); Pullulan

Indexed keywords

COVERED STENTS; GASTROINTESTINAL CANCER; GEMCITABINE; NONVASCULAR DRUG-ELUTING STENTS (DES); PULLULANS;

ACETYLATION; ARTIFICIAL ORGANS; CELL DEATH; DRUG DELIVERY; GEMS; GLUCOSE; HISTOLOGY; HYDROGELS; TUMORS;

DISEASES;

GEMCITABINE; LIPOCORTIN 5; POLITEF; PULLULAN; WATER;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RELATED STENOSIS; CONTACT ANGLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DRUG ACETYLATION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELUTING STENT; FIELD EMISSION SCANNING ELECTRON MICROSCOPY; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STENOSIS; TUMOR REGRESSION; TUMOR VOLUME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; COLONIC NEOPLASMS; CONSTRICTION, PATHOLOGIC; DEOXYCYTIDINE; DRUG-ELUTING STENTS; GASTROINTESTINAL NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; POLYSACCHARIDES; POLYTETRAFLUOROETHYLENE;

EID: 79952102879     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.01.070     Document Type: Article

References (40)

1. von Segesser L.K., Marty B., Tozzi P., Ruchat P. Impact of endoluminal stenting for aortic surgery. Eur J Cardiothorac Surg 2004, 26(Suppl. 1):S14-S17. discussion S7-8.
2. Htay T., Liu M. Drug-eluting stent: a review and update. Vasc Health Risk Manag 2005, 1:263-276.
3. Zilberman M., Eberhart R. Drug-eluting bioresorbable stents for various applications. Annu Rev Biomed Eng 2006, 8:153-180.
4. Tanaka T., Takahashi M., Nitta N., Furukawa A., Andoh A., Saito Y., et al. Newly developed biodegradable stents for benign gastrointestinal tract stenoses: a preliminary clinical trial. Digestion 2006, 74:199-205.
5. Silvis S., Sievert C., Vennes J., Abeyta B., Brennecke L. Comparison of covered versus uncovered wire mesh stents in the canine biliary tract. Gastroenterol Nurs 1994, 16:289.
6. Isayama H., Komatsu Y., Tsujino T., Sasahira N., Hirano K., Toda N., et al. A prospective randomised study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction. Gut 2004, 53:729-734.
7. Thurnher S., Lammer J., Thurnher M., Winkelbauer F., Graf O., Wildling R. Covered self-expanding transhepatic biliary stents: clinical pilot study. Cardiovasc Intervent Radiol 1996, 19:10-14.
8. Bezzi M., Zolovkins A., Cantisani V., Salvatori F., Rossi M., Fanelli F., et al. New ePTFE/FEP-covered stent in the palliative treatment of malignant biliary obstruction. J Vasc Interv Radiol 2002, 13:581-589.
9. Han Y., Jin G., Lee S., Kwak H., Chung G. Flared polyurethane-covered self-expandable nitinol stent for malignant biliary obstruction. J Vasc Interv Radiol 2003, 14:1291-1301.
10. Shin J., Song H., Kim J., Kim S., Lee G., Park S., et al. Comparison of temporary and permanent stent placement with concurrent radiation therapy in patients with esophageal carcinoma. J Vasc Interv Radiol 2005, 16:67-74.
11. van der Giessen W., Lincoff A., Schwartz R., van Beusekom H., Serruys P., Holmes D., et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996, 94:1690-1697.
12. Fischell T. Polymer coatings for stents: can we judge a stent by its cover?. Circulation 1996, 94:1494.
13. Manifold D., Maynard N., Cowling M., Machan L., Mason R., Adam A. Taxol coated stents in oesophageal adenocarcinoma. Gastroenterology 1998, 114:A27.
14. Lee D., Kim H., Kim K., Lee W., Kim H., Won Y., et al. The effect on porcine bile duct of a metallic stent covered with a paclitaxel-incorporated membrane. Gastrointest Endosc 2005, 61:296-301.
15. Suk K., Kim J., Kim H., Baik S., Oh S., Lee S., et al. Human application of a metallic stent covered with a paclitaxel-incorporated membrane for malignant biliary obstruction: multicenter pilot study. Gastrointest Endosc 2007, 66:798-803.
16. Xi K., Tabata Y., Uno K., Yoshimoto M., Kishida T., Sokawa Y., et al. Liver targeting of interferon through pullulan conjugation. Pharm Res 1996, 13:1846-1850.
17. Kim S., Park K., Ko J., Kwon I., Cho H., Kang D., et al. Minimalism in fabrication of self-organized nanogels holding both anti-cancer drug and targeting moiety. Colloids Surf B Biointerfaces 2008, 63:55-63.
18. Lee E., Na K., Bae Y. Polymeric micelle for tumor pH and folate-mediated targeting. J Control Release 2003, 91:103-113.
19. Lu D., Wen X., Liang J., Gu Z., Zhang X., Fan Y. A pH-sensitive nano drug delivery system derived from pullulan/doxorubicin conjugate. J Biomed Mater Res B Appl Biomater 2009, 89:177-183.
20. Hui Y., Reitz J. Gemcitabine: a cytidine analogue active against solid tumors. Am J Health Syst Pharm 1997, 54:162-170.
21. Heinemann V., Hertel L., Grindey G., Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2', 2'-difluorodeoxycytidine and 1-(beta)-D-arabinofuranosylcytosine. Cancer Res 1988, 48:4024-4031.
22. Fruscella E., Gallo D., Ferrandina G., D'Agostino G., Scambia G. Gemcitabine: current role and future options in the treatment of ovarian cancer. Crit Rev Oncol Hematol 2003, 48:81-88.
23. Veerman G., van Haperen V., Vermorken J., Noordhuis P., Braakhuis B., Pinedo H., et al. Antitumor activity of prolonged as compared with bolus administration of 2′, 2′-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol 1996, 38:335-342.
24. Carmichael J., Possinger K., Phillip P., Beykirch M., Kerr H., Walling J., et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995, 13:2731-2736.
25. Sternberg C.N. Gemcitabine in bladder cancer. Semin Oncol 2000, 27:31-39.
26. Hoang T., Kim K., Jaslowski A., Koch P., Beatty P., McGovern J., et al. Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer. Lung Cancer 2003, 42:97-102.
27. Carmichael J., Fink U., Russell R., Spittle M., Harris A., Spiessi G., et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Brit J Cancer 1996, 73:101-105.
28. Crin L., Calandri C. Gemzar platinum combinations: phase III trials in non-small cell lung cancer. Lung Cancer 2002, 38:9-12.
29. Pili B., Bourgaux C., Meneau F., Couvreur P., Ollivon M. Interaction of an anticancer drug, gemcitabine, with phospholipid bilayers. J Therm Anal Calorim 2009, 98:19-28.
30. Na K., Shin D., Yun K., Park K., Lee K. Conjugation of heparin into carboxylated pullulan derivatives as an extracellular matrix for endothelial cell culture. Biotechnol Lett 2003, 25:381-385.
31. Park K., Song H., Na K., Bom H., Lee K., Kim S., et al. Ionic strength-sensitive pullulan acetate nanoparticles (PAN) for intratumoral administration of radioisotope: Ionic strength-dependent aggregation behavior and 99mTechnetium retention property. Colloids Surf B Biointerfaces 2007, 59:16-23.
32. Le Tien C., Lacroix M., Ispas-Szabo P., Mateescu M.A. N-acylated chitosan: hydrophobic matrices for controlled drug release. J Control Release 2003, 93:1-13.
33. Okino H., Maeyama R., Manabe T., Matsuda T., Tanaka M. Trans-tissue, sustained release of gemcitabine from photocured gelatin gel inhibits the growth of heterotopic human pancreatic tumor in nude mice. Clin Cancer Res 2003, 9:5786-5793.
34. Brem H., Piantadosi S., Burger P., Walker M., Selker R., Vick N., et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas 1. Lancet 1995, 345:1008-1012.
35. Stone G., Moses J., Ellis S., Schofer J., Dawkins K., Morice M., et al. Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents. N Engl J Med 2007, 356:998-1008.
36. Hanauske A., Degen D., Marshall M., Hilsenbeck S., Grindey G., Von Hoff D. Activity of 2, 2-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units. Anti-Cancer Drugs 1992, 3:143-146.
37. Kornmann M., Butzer U., Blatter J., Beger H., Link K. Pre-clinical evaluation of the activity of gemcitabine as a basis for regional chemotherapy of pancreatic and colorectal cancer. Eur J Surg Oncol 2000, 26:583-587.
38. Huang P., Chubb S., Hertel L., Grindey G., Plunkett W. Action of 2', 2'-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991, 51:6110-6117.
39. Paolino D., Cosco D., Racanicchi L., Trapasso E., Celia C., Iannone M., et al. Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. J Control Release 2010, 144:144-150.
40. Baguley B., Finlay G. Pharmacokinetic/cytokinetic principles in the chemotherapy of solid tumours. Clin Exp Pharmacol Physiol 1995, 22:825-828.